title: Re: Atypical antipsychotic use in treating adolescents and young adults with developmental disabilities.
authors.forename: Elspeth A
authors.initials: EA
authors.lastname: Bradley
authors.forename: Yona
authors.initials: Y
authors.lastname: Lunsky
authors.forename: Joseph M
authors.initials: JM
authors.lastname: Berg
authors.forename: Robin W
authors.initials: RW
authors.lastname: Brooks-Hill
authors.forename: Donal A
authors.initials: DA
authors.lastname: O'Leary
authors.forename: Karen E
authors.initials: KE
authors.lastname: Harman
authors.forename: Marika
authors.initials: M
authors.lastname: Korossy
mesh_terms: D000293:Adolescent; D000328:Adult; D014150:Antipsychotic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D002170:Canada; D002658:Developmental Disabilities / Q000188:drug therapy* / Q000523:psychology; D004305:Dose-Response Relationship, Drug; D004409:Dyskinesia, Drug-Induced / Q000209:etiology; D005260:Female; D006801:Humans; D008607:Intellectual Disability / Q000188:drug therapy* / Q000523:psychology; D008134:Long-Term Care; D008297:Male; D016896:Treatment Outcome
chemical_list: D014150:Antipsychotic Agents